within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XK06_Pamiparib;

model Pamiparib
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.38,
    Cl = 4.361111111111111e-06,
    adminDuration = 600,
    adminMass = 60 / 1000000,
    adminCount = 1,
    Vd = 0.091,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.006266666666666667,
    Tlag = 12.9,
    Vdp = 0.0195,
    k12 = 7.555555555555555e-06,
    k21 = 7.555555555555555e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Pamiparib</td></tr><tr><td>ATC code:</td><td>L01XK06</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>60</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>91</td><td>L</td></tr>
    <tr><td>clearance:</td><td>15.7</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Pamiparib is an orally bioavailable, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes PARP1 and PARP2. It is indicated for the treatment of certain types of ovarian, fallopian tube, or primary peritoneal cancer, especially in patients with germline BRCA mutations, and is approved in some countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated in adult cancer patients after oral administration.</p><h4>References</h4><ol><li><p>Wickramasinghe, C, et al., &amp; Li, J (2025). Population Pharmacokinetic Modeling of Total and Unbound Pamiparib in Glioblastoma Patients: Insights into Drug Disposition and Dosing Optimization. <i>Pharmaceutics</i> 17(4) –. DOI:<a href=\"https://doi.org/10.3390/pharmaceutics17040524\">10.3390/pharmaceutics17040524</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/40284519/\">https://pubmed.ncbi.nlm.nih.gov/40284519</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01XK06 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Pamiparib;
